Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Denavir Advisory Cmte. Members Uncomfortable With Risk/Benefit Ratio

This article was originally published in The Tan Sheet

Executive Summary

A joint FDA advisory committee recommended against the Rx-to-OTC switch of SmithKline Beecham's Denavir in a narrow vote, with several members questioning whether the potential risks from broader access to the 1% penciclovir cream for cold sores may outweigh its benefits.
Advertisement

Related Content

NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
GSK, Galpharm Pioneer UK Nonprescription Omeprazole Market
GSK, Galpharm Pioneer UK Nonprescription Omeprazole Market
OTC Antiviral Agents For Herpes Cold Sores Disfavored By FDA
Healthcare "Rationing" Not Acceptable Reason For Denying Switches - FDAer
Consumer Recall Of OTC Advertising "Much Higher" Than DTC Ads In Study
OTC Switch Public Policy, Science Issues Workshop Proposed
Denavir

Topics

Advertisement
UsernamePublicRestriction

Register

PS089162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel